Tazemetostat is withdrawn from the market due to a risk of secondary malignancies.
RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference?
Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
Jun 2021
Review Series on Platelets and Cancer
Platelets are critical for hemostasis and thrombosis, but recent research highlights their role in many other processes, including inflammation, wound healing, and lymphangiogenesis. In this episode, Drs. José López, Elisabeth Battinelli, Craig Williams, and Owen McCarty discuss ... Show More
35m 27s
Oct 2025
NEJM This Week — October 16, 2025
In this episode, we look at new research in cervical cancer, lupus, gene therapy for immune deficiency, and malaria prevention in infants. We review hair loss in women, follow a case of tuberculosis in advanced HIV, and hear perspectives on vaccines, primary care, digital health, ... Show More
30m 33s
Sep 2025
Marsquakes, Vaccine Politics and Mammoth Microbiomes
This week’s roundup dives into Mars’s lumpy mantle, a nasal spray that may help prevent COVID and the growing confusion around vaccine access in the U.S. Plus, researchers link phone use while on the toilet to hemorrhoid risk, uncover ancient mammoth microbiomes and explain why s ... Show More
9m 45s
<p>In this episode, we review the high-yield topic of <a href="https://step2.medbullets.com/oncology/120467/acute-lymphoblastic-leukemia-all">Acute Lymphoblastic Leukemia (ALL)</a> from the Oncology section.</p>
<p>Follow <a href="https://step1.medbullets.com/">Medbullets</a> on ... Show More
